These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22037868)

  • 41. A chimeric RNA characteristic of rhabdomyosarcoma in normal myogenesis process.
    Yuan H; Qin F; Movassagh M; Park H; Golden W; Xie Z; Zhang P; Sklar J; Li H
    Cancer Discov; 2013 Dec; 3(12):1394-403. PubMed ID: 24089019
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PAX3/forkhead homolog in rhabdomyosarcoma oncoprotein activates glucose transporter 4 gene expression in vivo and in vitro.
    Armoni M; Quon MJ; Maor G; Avigad S; Shapiro DN; Harel C; Esposito D; Goshen Y; Yaniv I; Karnieli E
    J Clin Endocrinol Metab; 2002 Nov; 87(11):5312-24. PubMed ID: 12414908
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Negative correlation of single-cell
    Regina C; Hamed E; Andrieux G; Angenendt S; Schneider M; Ku M; Follo M; Wachtel M; Ke E; Kikuchi K; Henssen AG; Schäfer BW; Boerries M; Wagers AJ; Keller C; Hettmer S
    Life Sci Alliance; 2021 Sep; 4(9):. PubMed ID: 34187933
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alveolar rhabdomyosarcoma: morphoproteomics and personalized tumor graft testing further define the biology of PAX3-FKHR(FOXO1) subtype and provide targeted therapeutic options.
    Brown RE; Buryanek J; Katz AM; Paz K; Wolff JE
    Oncotarget; 2016 Jul; 7(29):46263-46272. PubMed ID: 27323832
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma.
    Nishijo K; Chen QR; Zhang L; McCleish AT; Rodriguez A; Cho MJ; Prajapati SI; Gelfond JA; Chisholm GB; Michalek JE; Aronow BJ; Barr FG; Randall RL; Ladanyi M; Qualman SJ; Rubin BP; LeGallo RD; Wang C; Khan J; Keller C
    Cancer Res; 2009 Apr; 69(7):2902-11. PubMed ID: 19339268
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular Cytogenetics Detect an Unbalanced t(2;13)(q36;q14) and PAX3-FOXO1 Fusion in Rhabdomyosarcoma With Mixed Embryonal/Alveolar Features.
    La Starza R; Nofrini V; Pierini T; Pierini V; Zin A; Bisogno G; Cerri C; Caniglia M; Sidoni A; Ludwig K; Mecucci C
    Pediatr Blood Cancer; 2015 Dec; 62(12):2238-41. PubMed ID: 26179572
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor.
    Roeb W; Boyer A; Cavenee WK; Arden KC
    Cell Cycle; 2008 Apr; 7(7):837-41. PubMed ID: 18414034
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alveolar rhabdomyosarcoma of the head and neck region in older adults: genetic characterization and a review of the literature.
    Yasuda T; Perry KD; Nelson M; Bui MM; Nasir A; Goldschmidt R; Gnepp DR; Bridge JA
    Hum Pathol; 2009 Mar; 40(3):341-8. PubMed ID: 18973919
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations.
    Ren YX; Finckenstein FG; Abdueva DA; Shahbazian V; Chung B; Weinberg KI; Triche TJ; Shimada H; Anderson MJ
    Cancer Res; 2008 Aug; 68(16):6587-97. PubMed ID: 18701482
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
    Laé M; Ahn EH; Mercado GE; Chuai S; Edgar M; Pawel BR; Olshen A; Barr FG; Ladanyi M
    J Pathol; 2007 Jun; 212(2):143-51. PubMed ID: 17471488
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The PAX3-FOXO1 fusion protein present in rhabdomyosarcoma interferes with normal FOXO activity and the TGF-β pathway.
    Schmitt-Ney M; Camussi G
    PLoS One; 2015; 10(3):e0121474. PubMed ID: 25806826
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sphingosine Induces Apoptosis and Down-regulation of
    Ahn EH; Lee MB; Seo DJ; Lee J; Kim Y; Gupta K
    Anticancer Res; 2018 Jan; 38(1):71-76. PubMed ID: 29277758
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy.
    Tonelli R; McIntyre A; Camerin C; Walters ZS; Di Leo K; Selfe J; Purgato S; Missiaglia E; Tortori A; Renshaw J; Astolfi A; Taylor KR; Serravalle S; Bishop R; Nanni C; Valentijn LJ; Faccini A; Leuschner I; Formica S; Reis-Filho JS; Ambrosini V; Thway K; Franzoni M; Summersgill B; Marchelli R; Hrelia P; Cantelli-Forti G; Fanti S; Corradini R; Pession A; Shipley J
    Clin Cancer Res; 2012 Feb; 18(3):796-807. PubMed ID: 22065083
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anlotinib destabilizes PAX3-FOXO1 to induce rhabdomyosarcoma cell death via upregulating NEK2.
    Song Z; Gong B; Qu T; Chen Y; Zhao G; Jin Y; Zhao Q
    Biomed Pharmacother; 2024 Aug; 177():117126. PubMed ID: 38996706
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PAX3 and PAX3-FKHR promote rhabdomyosarcoma cell survival through downregulation of PTEN.
    Li HG; Wang Q; Li HM; Kumar S; Parker C; Slevin M; Kumar P
    Cancer Lett; 2007 Aug; 253(2):215-23. PubMed ID: 17350164
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FANCD2 is a potential therapeutic target and biomarker in alveolar rhabdomyosarcoma harboring the PAX3-FOXO1 fusion gene.
    Singh M; Leasure JM; Chronowski C; Geier B; Bondra K; Duan W; Hensley LA; Villalona-Calero M; Li N; Vergis AM; Kurmasheva RT; Shen C; Woods G; Sebastian N; Fabian D; Kaplon R; Hammond S; Palanichamy K; Chakravarti A; Houghton PJ
    Clin Cancer Res; 2014 Jul; 20(14):3884-95. PubMed ID: 24787670
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glycogen synthase kinase 3β represses MYOGENIN function in alveolar rhabdomyosarcoma.
    Dionyssiou MG; Ehyai S; Avrutin E; Connor MK; McDermott JC
    Cell Death Dis; 2014 Feb; 5(2):e1094. PubMed ID: 24577092
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reduced B7-H3 expression by PAX3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcoma.
    Kanayama T; Miyachi M; Sugimoto Y; Yagyu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
    Sci Rep; 2021 Sep; 11(1):18802. PubMed ID: 34552155
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma.
    Bois PR; Izeradjene K; Houghton PJ; Cleveland JL; Houghton JA; Grosveld GC
    J Cell Biol; 2005 Sep; 170(6):903-12. PubMed ID: 16157701
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma.
    Kikuchi K; Tsuchiya K; Otabe O; Gotoh T; Tamura S; Katsumi Y; Yagyu S; Tsubai-Shimizu S; Miyachi M; Iehara T; Hosoi H
    Biochem Biophys Res Commun; 2008 Jan; 365(3):568-74. PubMed ID: 18022385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.